Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.

Molecular cancer therapeutics - 1 Dec 2014

Kodama Tatsushi, Tsukaguchi Toshiyuki, Satoh Yasuko, Yoshida Miyuki, Watanabe Yoshiaki, Kondoh Osamu, Sakamoto Hiroshi

Abstract excerpt

Alectinib/CH5424802 is a known inhibitor of anaplastic lymphoma kinase (ALK) and is being evaluated in clinical trials for the treatment of ALK fusion-positive non-small cell lung cancer (NSCLC). Recently, some RET and ROS1 fusion genes have been implicated as driver oncogenes in NSCLC and have become molecular targets for antitumor agents. This study aims to explore additional target indications of alectinib by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carbazoles
Share to Gene Rearrangement

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Conformation

Share to Oncogene Proteins, Fusion

Share to Piperidines

Share to Proto-Oncogene Proteins c-ret

Share to Receptor Protein-Tyrosine Kinases

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 25349307
DOI: 10.1158/1535-7163.MCT-14-0274

Genes

RET
ALK
ROS1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.PMID 25349307Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapySemantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.Semantic proximity Read ↗

Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.Semantic proximity Read ↗

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion KinasesSemantic proximity Read ↗

Alectinib for treatment of ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.Semantic proximity Read ↗

Novel targets in non-small cell lung cancer: ROS1 and RET fusions.Semantic proximity Read ↗

Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.Semantic proximity Read ↗

Mixed responses to first‐line alectinib in non‐small cell lung cancer patients with rare ALK gene fusions: A case series and literature reviewSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.